Nurix Therapeutics, Inc.
NRIX
$9.55
$0.020.21%
NASDAQ
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 22.87% | 3.75% | -19.60% | -9.90% | -7.29% |
| Total Depreciation and Amortization | 23.47% | 37.46% | -27.57% | 1.34% | 5.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.77% | 2.36% | -5.40% | -20.22% | 13.48% |
| Change in Net Operating Assets | -131.51% | -3,224.50% | 116.62% | 54.50% | 41.88% |
| Cash from Operations | -3.40% | -25.30% | -15.59% | -6.23% | 5.35% |
| Capital Expenditure | 23.24% | -65.56% | 10.31% | -21.17% | 32.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 155.61% | 120.92% | -630.37% | 85.29% | -436.31% |
| Cash from Investing | 180.03% | 118.13% | -559.90% | 83.72% | -469.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.59% | -99.27% | 338.11% | -80.75% | 14,540.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.59% | -99.27% | 338.11% | -80.75% | 14,539.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 124.48% | -411.16% | 161.72% | -126.50% | 1,491.30% |